{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:11:33Z","timestamp":1777961493488,"version":"3.51.4"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer (PC) is characterized by a highly immunosuppressive microenvironment, limiting the efficacy of immunotherapy. T-cell regulation plays a pivotal role in anti-tumor immunity. However, the prognostic value and therapeutic implications of T-cell regulation-related genes (TRGs) in PC remain largely unexplored. This study aims to construct a TRG-based risk model and validate key therapeutic targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transcriptomic profiles and clinical data were retrieved from TCGA and GEO databases. Non-negative Matrix Factorization (NMF) clustering was performed to identify molecular subtypes. A prognostic risk signature was constructed using LASSO regression analysis. The immune landscape was evaluated via ssGSEA, CIBERSORT and TIDE algorithms. A nomogram was established to predict overall survival, and drug sensitivity was assessed based on IC50 estimation. Crucially, the expression of the key signature gene IL1RN was validated in clinical tissues using qRT-PCR, Western Blot, and immunohistochemistry (IHC). Its function in T-cell mediated cytotoxicity was further verified using co-culture assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two distinct molecular subtypes were identified, with Cluster 1 exhibiting an immune-hot phenotype and superior survival. A robust risk model was constructed and validated, serving as an independent prognostic factor. High-risk patients were characterized by an immune-excluded phenotype but showed higher sensitivity to chemotherapeutic agents like Gemcitabine. Experimental validation confirmed that IL1RN was significantly upregulated in PC tissues. Functionally, knockdown of IL1RN significantly enhanced the cytotoxicity of T cells against pancreatic cancer cells\n                      <jats:italic>in vitro<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We constructed a novel TRG-based prognostic signature that can serve as an auxiliary tool for clinical prognostic evaluation in pancreatic cancer. Furthermore, we validated IL1RN as a critical mechanism of immune resistance. IL1RN is expected to become a novel target for pancreatic cancer immunotherapy, providing experimental evidence for the stratified treatment of PC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1800810","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:31:19Z","timestamp":1777959079000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value and immunological significance of t-cell proliferation regulators in pancreatic cancer: a novel predictive model"],"prefix":"10.3389","volume":"13","author":[{"given":"Wenyi","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingeng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiacheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yike","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyang","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants.","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016.","volume":"2","author":"Zheng","year":"2022","journal-title":"J Natl Cancer Cent."},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer.","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial.","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","article-title":"The pancreas cancer microenvironment.","volume":"18","author":"Feig","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/s0360-3016(00)00803-8","article-title":"Pancreatic tumors show high levels of hypoxia.","volume":"48","author":"Koong","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges.","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41575-021-00431-7","article-title":"Harnessing metabolic dependencies in pancreatic cancers.","volume":"18","author":"Encarnaci\u00f3n-Rosado","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature."},{"key":"B14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer.","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1158\/0008-5472.CAN-16-0658","article-title":"The genomic landscape of pancreatic and periampullary adenocarcinoma.","volume":"76","author":"Sandhu","year":"2016","journal-title":"Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion.","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","article-title":"Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer.","volume":"1","author":"Steele","year":"2020","journal-title":"Nat Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","article-title":"The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer.","volume":"39","author":"Freed-Pastor","year":"2021","journal-title":"Cancer Cell."},{"key":"B19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","article-title":"Metabolic coordination of T cell quiescence and activation.","volume":"20","author":"Chapman","year":"2020","journal-title":"Nat Rev Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","article-title":"CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions.","volume":"69","author":"Hashimoto","year":"2018","journal-title":"Annu Rev Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T Cell dysfunction in cancer.","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell."},{"key":"B22","doi-asserted-by":"publisher","first-page":": 185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Electronic address aadhe, cancer genome atlas research N: integrated genomic characterization of pancreatic ductal adenocarcinoma.","volume":"32","year":"2017","journal-title":"Cancer Cell."},{"key":"B23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.tibs.2017.11.008","article-title":"TCR signaling: mechanisms of initiation and propagation.","volume":"43","author":"Courtney","year":"2018","journal-title":"Trends Biochem Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease.","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct Target Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: a case for priming, not checkpoint.","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell."},{"key":"B28","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy.","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell."},{"key":"B29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-022-04494-7","article-title":"A genome-scale screen for synthetic drivers of T cell proliferation.","volume":"603","author":"Legut","year":"2022","journal-title":"Nature."},{"key":"B30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters.","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS."},{"key":"B31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT.","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol."},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies.","author":"Harrell","year":"2015"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gene.2019.02.081","article-title":"High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma.","volume":"701","author":"Piao","year":"2019","journal-title":"Gene."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1000307","DOI":"10.1371\/journal.pmed.1000307","article-title":"A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.","volume":"7","author":"Stratford","year":"2010","journal-title":"PLoS Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.7150\/jca.31291","article-title":"Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition.","volume":"10","author":"Zhang","year":"2019","journal-title":"J Cancer."},{"key":"B37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","article-title":"Immunotherapy and prevention of pancreatic cancer.","volume":"4","author":"Morrison","year":"2018","journal-title":"Trends Cancer."},{"key":"B38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity.","volume":"548","author":"Goel","year":"2017","journal-title":"Nature."},{"key":"B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity.","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/imr.12614","article-title":"IL-1 and IL-1 regulatory pathways in cancer progression and therapy.","volume":"281","author":"Mantovani","year":"2018","journal-title":"Immunol Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1800810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:31:20Z","timestamp":1777959080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1800810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":41,"alternative-id":["10.3389\/fmed.2026.1800810"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1800810","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"article-number":"1800810"}}